scholarly journals Rectal cream “Hem” (as suppositories) in treatment of chronic abacterial prostatitis

2021 ◽  
Vol 22 (4) ◽  
pp. 97-102
Author(s):  
N. P. Naumov ◽  
P. A. Scheplev ◽  
S. К. Martazinova
Keyword(s):  
Chronic Prostatitis ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Reproductive Age ◽  
Pelvic Pain Syndrome ◽  
Russian Company ◽  
Study Objective ◽  
Bacterial Agent ◽  
Lower Urinary

Chronic prostatitis is one of the most common disorders in men of reproductive age. In 5-10 % of cases, prostatitis is caused by bacterial infection. In 80-90 % of patients, bacterial agent cannot be detected, and chronic abacterial prostatitis is diagnosed per the National Institute of Health classification (NIH, 1995).Even with combination therapy using drugs of different groups, chronic prostatitis is a recurrent disorder and can lead to development of symptoms in the lower urinary tract and chronic pelvic pain syndrome decreasing patients' quality of life.Phytotherapy and beekeeping products with anti-inflammatory, pain-relieving, immunostimulating effects has a certain place in the treatment of chronic prostatitis.The study objective is to evaluate the effectiveness and safety of rectal cream “Hem” (as suppositories) manufactured by Russian company ADONIS CNPG and TM LCC in patients with chronic abacterial prostatitis.

87: Biopsychosocial Factors in Quality of Life in men with Chronic Prostatitis/Chronic Pelvic Pain Syndrome

2007 ◽  
Vol 177 (4S) ◽  
pp. 31-31
Author(s):  
J. Curtis Nickel ◽  
Dean Tripp ◽  
Shannon Chuai ◽  
Mark S. Litwin ◽  
Mary McNaughton-Collins
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome

scholarly journals Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome

2018 ◽  
Vol 10 (12) ◽  
pp. 377-381 ◽  
Author(s):  
Andrea Benelli ◽  
Simone Mariani ◽  
Virginia Varca ◽  
Andrea Gregori ◽  
Franco Barrese ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Once Daily ◽  
International Prostatic Symptom Score

Background: Chronic prostatitis/chronic pelvic pain syndrome (IIIB CP/CPPS) is a condition of unclear aetiology. Many approaches have been used without satisfactory results. The aim of this study is to evaluate the efficacy of once-daily 5 mg tadalafil in pain control and improving quality of life in patients affected by CP/CPPS. Methods: Twenty patients affected by chronic prostatitis according EAU (European Association of Urology) guidelines were evaluated for once-daily 5 mg tadalafil; 14 patients were eligible for the study. The validated Italian version of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and the International Prostatic Symptom Score (IPSS) questionnaires were submitted to all the patients. Every patient underwent uroflowmetry and ultrasound prostatic volume at the beginning and at the end of the study. Results: All 14 patients eligible for the study reported an improvement of symptoms during therapy: statistically significant differences were reported in terms of NIH-CPSI ( p < 0.000002) and IPSS ( p < 0.0001) during follow-up evaluations. No statistically significant improvement of uroflowmetry parameters was reported during the treatment. Conclusions: In our study the daily use of 5 mg tadalafil improves symptoms and quality of life in patients affected by CP/CPPS after 4 weeks of therapy. A larger population of patients is needed to confirm the efficacy of this therapy in CP/CPPS.

scholarly journals Efficacy of pollen extract in association with group B vitamins for pain relief in chronic prostatitis/chronic pelvic pain syndrome: A survey of urologists' knowledge about its clinical application

2017 ◽  
Vol 89 (1) ◽  
pp. 22 ◽  
Author(s):  
Giacomo Maria Pirola ◽  
Stefano Puliatti ◽  
Tommaso Bocchialini ◽  
Eugenio Martorana ◽  
Salvatore Micali ◽  
...  
Keyword(s):  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
B Vitamins ◽  
Pelvic Pain Syndrome ◽  
Plant Product ◽  
Group B ◽  
Group B Vitamins

Introduction and aim of the study: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPSS) is a pathology of high prevalence in Italian male population, difficult to diagnose and to treat and with poor response to conventional therapy. Aim of this study was to review the evidence of the literature about the therapeutic effects of a plant product containing flower pollen extracts and group B vitamins on symptoms resolution and amelioration of CP/CPPS patients’ quality of life and to investigate the knowledge among practicing urologists about the clinical application of this product. Materials and methods: A group of 38 urologists was submitted to an investigational survey of the knowledge of the clinical applications of a plant product containing flower pollen extracts and group B vitamins Results: 71% of the urologists interviewed prescribed the plant product for CBP and CP/CPPS at least one time in a month and 11% prescribed it more than 5 times; 67% had evidence of clear ameliorations in pain relief and on patient's quality of life and 47% reported that the effectiveness is comparable to NSAIDs; 39% also reported a significant effect for the improvement of the urinary symptoms of patients. No gastric or general side effects have been noticed during the administration period of this plant product. Finally, the cost of the product has always reported to be sustainable for the patients. Conclusions: From the results of this investigational survey, we can state that the plant product containing flower pollen extracts and group B vitamins is well-known and demonstrated beneficial effects on symptoms resolution and amelioration of quality of life in patients with chronic prostatitis/chronic pelvic pain syndrome.

scholarly journals The effectiveness of non-steroidal anti-inflammatory drugs in the treatment of chronic pelvic pain syndrome

2018 ◽  
pp. 111-115
Author(s):  
T.G. Romanenko ◽  
◽  
O.M. Sulimenko ◽  
Keyword(s):  
Pelvic Pain ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Antiplatelet Agents ◽  
Reproductive Age ◽  
Pelvic Pain Syndrome ◽  
Group I ◽  
Inflammatory Drugs

Evidence-based medicine is an approach to medical practice in which the decision on the appointment of therapeutic, diagnostic or preventive measures is based on the evidence of their effectiveness and safety. The objective: assessment of the effectiveness and safety of the use of NSAIDs in the treatment of chronic pelvic pain in women of reproductive age. Materials and methods. Under our supervision, there were 101 women of reproductive age with chronic pelvic pain syndrome (CPPS) on the background of chronic inflammatory processes of the pelvic organs. Patients, depending on the received treatment, were randomly divided into two groups: Group I (n=54) – complex antibiotic (AB) therapy was conducted in combination with antiplatelet agents, antihypoxants, analgesics; Group II (n=47) – complex antibiotic (AB) therapy was performed in combination with antiplatelet agents, antihypoxants and NSAIDs (DICLOSAFE, diclofenac sodium 100 mg). The exclusion criterion was the presence of an endometriosis in a patient. When patients were included in the study and 6 months after the completion of the treatment, a questionnaire was conducted to determine the severity of the pain syndrome, psychological status and quality of life. Results. Positive dynamics of quantitative and qualitative characteristics of the pain syndrome, as well as dynamics of its intensity as a result of conservative treatment for 6 months in group ІІ, was noted. Also, in group ІІ, statistically significant data on the reduction of depression and personal anxiety are noted, in contrast to the indicators of group I. The results of the questionnaire of patients in group II after treatment indicated improvement of all components of physical health. Statistically significant differences with the indicators of Group I were obtained on the scale of the effect of pain on daily activity (BP). In addition, after treatment in the II group, the patients showed statistically significant changes in mental health and all its components: vital activity (VT), social activity (SF), limitation of daily activity due to emotional problems (RE) and mental health I (MH). Conclusion. Pathogenetically grounded use of NSAIDs (DICLOSAFE suppositories) in the complex treatment of patients with CPPS allows to achieve a significant improvement in quality of life indicators due to the correction of pain syndrome. Key words: chronic pelvic pain syndrome, treatment, nonsteroidal anti-inflammatory drugs.

scholarly journals The role of nutraceutical medications in men with non bacterial chronic prostatitis and chronic pelvic pain syndrome: A prospective non blinded study utilizing flower pollen extracts versus bioflavonoids

2019 ◽  
Vol 90 (4) ◽  
pp. 260-264 ◽  
Author(s):  
Angela Maurizi ◽  
Francesco De Luca ◽  
Antonino Zanghi ◽  
Emy Manzi ◽  
Costantino Leonardo ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Waiting Time ◽  
Chronic Prostatitis ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Symptom Index ◽  
Average Waiting Time

Introduction: Chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS) represents a challenge for the urologist, since the therapeutic efficacy does not always result in a satisfactory quality of life for the patients. Often the side effects of the medications used (antiinflammatories, antibiotics, alpha blockers) far outweighs the benefits gained with their admission. The choice of nutraceutical medications is preferred for their effectiveness, that has been accepted and proven by the scientific community, and for the low incidence of side effects. The objective of this study to compare the therapeutic efficacy of the flower pollen extracts (Deprox®) versus Bioflavonoids in terms of reduction of symptoms, and in the average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and to evaluate the quality of life improvement of the patients affected by CP/CPPS. Methods: Among the 68 patients presented with prostatic symptoms to the Hospital “Umberto I” in Rome, Italy between March 2016 and June 2016, 54 patients met the clinical diagnosis of CP/CPPS (class IIIa or IIIb according to the NIH classification). The patients were assigned to either treatment with Deprox® or quercetin based on a randomization scheme previously determined.The NIH- CPSI, IPSS, QoL questionnaires were administered. Every patient underwent bacterial cultures and trans-rectal ultrasound. Results: There was a statistically significant improvement of the NIH-CPSI score and QoL in the Deprox® group (p = < 0.0001 and p = 0.003 respectively). The average waiting time of the variation of the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was statistically significant (p = 0.0019). In the absence of efficacy of the “conventional” medications, which also carries significant side effects, the dietary supplements may represent a valid alternative. Conclusions: DEPROX® has demonstrated a significant improvement of the symptoms and quality of life of patients diagnosed with by CP/CPPS. Furthermore, there was a statistical difference in the average waiting time of the variation of the NIH-CPSI) score without side effects as compared to the bioflavonoids complex with quercetin.

scholarly journals Flower Pollen Extract in Association with Vitamins (Deprox 500®) Versus Serenoa repens in Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Comparative Analysis of Two Different Treatments

2019 ◽  
Vol 18 (2) ◽  
pp. 151-161 ◽  
Author(s):  
Nicola Macchione ◽  
Paolo Bernardini ◽  
Igor Piacentini ◽  
Barbara Mangiarotti ◽  
Alberto Del Nero
Keyword(s):  
Chronic Prostatitis ◽  
Chronic Pelvic Pain ◽  
Outcome Measure ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Pollen Extract ◽  
Serenoa Repens ◽  
The Mean

Objective: Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) is reported in the literature ranging from 1 to 14.2%. The aim of the present study was to assess the impact on patient’s quality of life and symptoms of Flower pollen extract in association with vitamins (Deprox 500®) in comparison with Serenoa repens 320 mg (Permixon 320 mg® by Pierre Fabre) in patients with CP/CPPS. Methodology: All consecutive patients, with a diagnosis of CP/CPPS, referred to our center from January to August 2016, were screened to be enrolled in this single-center, randomized, controlled trial. The main outcome measure was the evaluation of IPSS/NIHCPSI (International Prostatic Symptom Score/NIH-Chronic Prostatitis Symptom Index) score variation and the assessment of the quality of life and symptoms at the end of the therapy. The second outcome measure was the evaluation of the comorbidity role in the CP/CPPS therapy. 63 patients were analyzed; patients were randomized into two groups: 29 patients were treated with Deprox 500® 2 tablets/day for 6 weeks and 34 patients with Serenoa repens 320 mg, 1 tablet/day for 6 weeks. Results: The mean score variation for IPSS was -12.7 ± 4.3 in the Deprox 500® group and -7.8 ± 4.7 in the Serenoa repens group (p=0.0005) while for NIH-CPSI was -17.3±3.1 in the Deprox 500® group and -13.6±4.8 in the Serenoa repens group (p=0.0016). By accounting only the symptoms part of NIH-CPSI questionnaire, the mean score variation reported was -11.5±2.5 in the Deprox 500® group and -9.02±4.0 in the Serenoa repens group (p=0.009321). Furthermore, analyzing the comorbidity subgroups, in patients with hypertension, the mean IPSS score variation was -14.3±3.2 in the Deprox 500® group and - 9.02±4.0 in the Serenoa repens group. Conclusion: In conclusion, in patients with CP/CPPS, Deprox 500® improves IPSS and NIH-CPSI scores up to 74.5% and 84.5% respectively. Furthermore, in patients with hypertension, the antioxidant effect of Deprox 500® reduces the mean IPSS score of 82.7%.

scholarly journals Effect of regimenal intervention by nutool (irrigation) in a case of chronic prostatitis/chronic pelvic pain syndrome

2019 ◽  
Vol 9 (2) ◽  
pp. 390-393
Author(s):  
Shabnam Ansari ◽  
Minhaj Ahmad ◽  
Asia Sultana ◽  
Mohammad Maaz ◽  
Fasihuzaman ----- ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Pelvic Pain ◽  
Chronic Prostatitis ◽  
Lower Urinary Tract ◽  
Chronic Pelvic Pain ◽  
Chronic Pelvic Pain Syndrome ◽  
Pain Syndrome ◽  
Pelvic Pain Syndrome ◽  
Lower Urinary

Background ‘Nutool’ is one of the regimenal therapy used in Unani medicine since centuries in various inflammatory and painful conditions. Chronic prostatitis (Warm-e- Gudda Mazi Muzmin) is associated with ‘chronic pelvic pain syndrome’ (CP/CPPS), is a chronic pain condition of non-bacterial origin in men with mixture of other symptoms such as lower urinary tract voiding, ejaculatory ailments and negative impact on quality of life (QOL), which almost lacks uniform effective therapy in conventional medicine. Objectives The purpose of our case study was to assess the impact of nutool in CP/ CPPS refractory to standard therapies and collect data to warrant further research in this area.        Case study  A 30 yrs. old Asian male admitted with symptoms of pelvic pain and pain during ejaculation from 6 month in absence of lower urinary tract symptoms with negative thoughts, diagnosed as CP/ CPPS on the protocols of NIH. Nutool of anti-inflammatory Unani drugs was given as the main therapy, daily for two weeks. Thus we report our case experience with the integrated short, review of literature and validated assessment, based on 1) VAS, 2) NIH-CPSI which includes pain index, urinary, and QOL score. Results Results were validated over the pain on the basis of VAS (visual analogue scale) and NIH-CPSI (standard questionnaire of the national institute of health—chronic prostatitis symptom index) which showed significant improvement after 2 weeks of therapy. Conclusion The preliminary findings, although limited, suggest the potential therapeutic role of Nutool in the treatment of CP/CPPS.

Sign in / Sign up

Export Citation Format

Share Document